The review concluded that silodosin was effective for lower urinary tract symptoms in men with benign prostatic hyperplasia (non-malignant prostate enlargement), but that the incidence of retrograde ejaculate was higher than with placebo or tamsulosin. The authors appropriately acknowledged that the small volume of short-term evidence of unknown quality may weaken the reliability of their findings, which seems appropriate.
Authors' objectives
To evaluate the efficacy and safety of silodosin for lower urinary tract symptoms in men with benign prostatic hyperplasia.
Searching
PubMed, EMBASE (from inception up to December 2011) and The Cochrane Library (2011, Issue 12) were searched. Search terms were reported. Reference lists of retrieved articles were examined. The search was not restricted by publication year or language.
Study selection
Randomised controlled trials (RCTs) that compared silodosin versus placebo or other medical treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia were eligible for inclusion. Randomised crossover trials were excluded. Outcome measures of interest were the International Prostate Symptom Score (IPSS), overall quality of life (QoL) score, peak urine maximum flow rate (Qmax) and quality of life specifically related to urinary symptoms and adverse effects.
All the included trials used 8mg of silodosin; comparators were placebo or tamsulosin (0.2mg). Trials were conducted in Europe, USA and Asia. All trials were of 12 weeks' duration. The mean age of participants ranged from 64.6 to 67.5 years.
Two reviewers independently selected relevant studies; any disagreements were resolved by consultation with a third reviewer.
Assessment of study quality
Trial quality was assessed using the Cochrane Risk of bias tool.
Two reviewers independently assessed study quality.
Data extraction
Data were extracted to calculate risk ratios for dichotomous outcomes and mean difference for continuous outcomes, each with 95% confidence intervals.
Two reviewers independently extracted the data.
Methods of synthesis
Pooled risk ratios, mean differences and their corresponding 95% confidence intervals were calculated using a fixedeffect (where there was no evidence of heterogeneity) or a random-effects model. Heterogeneity was assessed using Χ² and Ι².
Results of the review
Four RCTs were included in the review (2,504 patients; 1,109 in the silodosin group, 736 in the placebo group and 659 in the tamsulosin group). Randomisation, allocation concealment, selective outcome reporting and other sources of bias were unclear for most of the included trials. All trials were double-blinded.
